These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 14107743)

  • 21. International collaborative assay of the international reference preparation of anti-yellow-fever serum.
    Krag P; Macnamara FN; Lyng J; Bentzon MW; Larsen SO
    Bull World Health Organ; 1965; 33(2):243-55. PubMed ID: 5294595
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A SERUM INHIBITOR IN ANIMAL AND HUMAN SERA OF BOVINE ENTEROVIRUSES. II. IN VIVO ACTIVITY AND ROLE IN "NATURAL" RESISTANCE TO INFECTION.
    KLEIN M; DEFOREST A
    J Immunol; 1964 May; 92():822-6. PubMed ID: 14170425
    [No Abstract]   [Full Text] [Related]  

  • 23. Collaborative study for the establishment of the WHO 3(rd) International Standard for Endotoxin, the Ph. Eur. endotoxin biological reference preparation batch 5 and the USP Reference Standard for Endotoxin Lot H0K354.
    Findlay L; Desai T; Heath A; Poole S; Crivellone M; Hauck W; Ambrose M; Morris T; Daas A; Rautmann G; Buchheit KH; Spieser JM; Terao E
    Pharmeur Bio Sci Notes; 2015; 2015():73-98. PubMed ID: 26830160
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serodifferentiation of poliovirus strains. I. Modified Wecker test on types 1 and 2 poliovirus strains.
    Kitahara T; Hara M; Nakao C; Soda K; Tagaya I
    Jpn J Med Sci Biol; 1967 Oct; 20(5):349-76. PubMed ID: 4295438
    [No Abstract]   [Full Text] [Related]  

  • 25. POLIOVIRUS VARIATION AND THE PRODUCTION OF ATTENUATED STRAINS FOR VACCINES.
    HOSKINS JM
    Curr Med Drugs; 1963 Apr; 3(8):15-21. PubMed ID: 14087455
    [No Abstract]   [Full Text] [Related]  

  • 26. PROBLEMS IN THE DEVELOPMENT AND USE OF ORAL POLIOVIRUS VACCINE.
    SABIN AB
    Clin Pharmacol Ther; 1963; 4():573-9. PubMed ID: 14060197
    [No Abstract]   [Full Text] [Related]  

  • 27. [PECULIARITIES IN VIRUS EXCRETION AND ANTIBODY FORMATION AFTER ADMINISTRATION OF A "BALANCED" LIVE VACCINE MIXTURE OF POLIOVIRUS TYPES I AND II].
    HENIGST W; MUELLER F; WUERSCHING F
    Z Hyg Infektionskr; 1963 Dec; 149():383-400. PubMed ID: 14123271
    [No Abstract]   [Full Text] [Related]  

  • 28. Paralysis after oral poliomyelitis vaccine.
    HINTON GG; DUNCAN IB; RATHBUN JC
    Can Med Assoc J; 1962 Oct; 87(17):915-6. PubMed ID: 13954690
    [No Abstract]   [Full Text] [Related]  

  • 29. New assays for the quality control of live oral poliovirus vaccine.
    Furesz J; Levenbook I
    Acta Microbiol Immunol Hung; 1998; 45(3-4):391-9. PubMed ID: 9873944
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [THE EFFECT OF PREVACCINAL IMMUNITY ON VIRAL EXCRETION AND ANTIBODY FORMATION FOLLOWING TYPE I ORAL POLIOVIRUS VACCINATION (SABIN)].
    SIEGERT R; ENDERS-RUCKLE G; OEHME J; WALLER HD
    Dtsch Med Wochenschr; 1963 Aug; 88():1586-94. PubMed ID: 14047334
    [No Abstract]   [Full Text] [Related]  

  • 31. [SEROLOGIC EFFECTIVENESS OF LIVE MONOVALENT POLIOVIRUS VACCINATION IN THE ORDER OF TYPE 2-3-1 AND 1-3-2].
    FORNOSI F; TALOS I
    Orv Hetil; 1964 Oct; 105():1878-82. PubMed ID: 14195777
    [No Abstract]   [Full Text] [Related]  

  • 32. POLIOVIRUS SHEDDING AND SEROCONVERSION. STUDIES OF 816 COSTA RICAN CHILDREN FED TRIVALENT VACCINE.
    ROCA-GARCIA M; MARKHAM FS; COX HR; VARGAS-MENDEZ O; GUEVARA EC; MONTOYA JA
    JAMA; 1964 May; 188():639-46. PubMed ID: 14121285
    [No Abstract]   [Full Text] [Related]  

  • 33. THE SECOND INTERNATIONAL STANDARD FOR PROLACTIN.
    BANGHAM DR; MUSSETT MV; STACK-DUNNE MP
    Bull World Health Organ; 1963; 29(6):721-8. PubMed ID: 14107744
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IN VITRO MARKER OF POLIOVIRUSES OBTAINED FROM HUMAN STOOLS AFTER ADMINISTRATION OF ATTENUATED LIVE POLIOVIRUS VACCINE (SABIN).
    KASAHARA S; YOSHIOKA I; YAMAGISHI H; AIZAWA C
    Kitasato Arch Exp Med; 1963 Dec; 36():77-86. PubMed ID: 14318783
    [No Abstract]   [Full Text] [Related]  

  • 35. POLIOVIRUS VACCINES AND THE CONTROL OF POLIOMYELITIS.
    STUART-HARRIS CH
    Proc R Soc Med; 1964 Jun; 57(6):459-62. PubMed ID: 14190860
    [No Abstract]   [Full Text] [Related]  

  • 36. [FIELD TRIAL WITH LIVE ORAL POLIOVIRUS VACCINE. II. PRODUCTION OF NEUTRALIZING ANTIBODIES FOLLOWING THE ADMINISTRATION OF MONOVALENT ORAL POLIOVIRUS VACCINE].
    OGAWA M; KANNO T; URASAWA S
    Sapporo Igaku Zasshi; 1963 Mar; 23():202-9. PubMed ID: 14057343
    [No Abstract]   [Full Text] [Related]  

  • 37. MARKER TEST OF POLIOVIRUS IN RELATION TO MASS VACCINATION WITH LIVE ORAL VACCINES.
    TOYOSHIMA K; MITSUDA B; TADOKORO J; YAMADA T; KUNITA N
    Biken J; 1963 Jul; 6():57-72. PubMed ID: 14147706
    [No Abstract]   [Full Text] [Related]  

  • 38. [EXPERIENCES WITH A NEW ATTENUATED POLIOVIRUS TYPE 3 USOL-D BAC DEVELOPED IN CZECHOSLOVAKIA].
    VONKA V; JANDA Z; SIMON J; ADAM E; ZAVADOVA H; ADAMOVA V; STAREK M
    Cesk Epidemiol Mikrobiol Imunol; 1964 Nov; 13():358-69. PubMed ID: 14241623
    [No Abstract]   [Full Text] [Related]  

  • 39. International reference preparation of anti-Mycoplasma gallisepticum serum.
    Stewart DL; Davidson I; Hebert CN; Frerichs CC
    Bull World Health Organ; 1971; 45(2):219-32. PubMed ID: 5316619
    [TBL] [Abstract][Full Text] [Related]  

  • 40. International reference preparation of anti-Newcastle-disease serum.
    Stewart DL; Hebert CN; Davidson I
    Bull World Health Organ; 1968; 38(6):925-34. PubMed ID: 5303666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.